II. Risk Factors: Medication-Induced Torsades de Pointes
- Female gender
- Elderly
- Hypokalemia
- Hypocalcemia
- Severe Hypomagnesemia
- Hepatic or renal dysfunction
- Bradycardia
- Atrial Fibrillation Cardioversion recently
- Congestive Heart Failure with Reduced Ejection Fraction (HFrEF)
- Left Ventricular Hypertrophy
- Recent Myocardial Infarction
- Concurrent Digoxin use
- Concurrent Diuretic use
- Baseline QT Prolongation or subclinical Long QT
- Multiple concurrent agents that prolong QT
- Rapid infusion of agents known to cause Prolonged QT
- Higher doses of predisposing drug raise risk
III. Causes: Cardiovascular agents
- Diuretics
- Vasodilators
- Antiarrhythmics (all are considered higher risk)
IV. Causes: Antiemetics
- Phenothiazines
- Ondansetron (Zofran)
- Dolasetron (Anzemet)
- Granisetron
- If QTc is already prolonged, Metoclopramide (Reglan), Palonosetron (Aloxi), Prochlorperazine are safe alternatives
- 5HT3 agents are unlikely to cause harm (even at highest dose, Ondansetron prolongs QTc only 20 ms)
V. Causes: Psychiatric Agents
-
Antipsychotics
- Highest risk: Thioridazine, Pimozide, Haloperidol, chlorperazine
- Some risk: Ziprasidone (Geodon), Fanapt, Invega, Saphris, Seroquel
- Consider lower risk agents: Abilify, Latuda, Zyprexa
-
Antidepressants
- Highest risk
- Tricyclic Antidepressants (Amitriptyline, Desipramine)
- Trazodone
- Fluoxetine (Prozac)
- Citalopram and Escitalopram (especially in combination with Cytochrome P450 2C19)
- Limit Citalopram (Celexa) to 20-40 mg/day
- Limit Escitalopram (Lexapro) to 10-20 mg/day
- Some risk
- Venlafaxine
- SSRIs in general
- Consider lower risk agents: Bupropion, Duloxetine, Mirtazapine
- Highest risk
VI. Causes: Antimicrobials
-
Fluoroquinolones
- Class effect (includes Levofloxacin, Moxifloxacin)
- Consider lower risk agent: Ciprofloxacin
-
Macrolides
- Includes Clarithromycin, Erythromycin, Azithromycin
- Three fold increased risk of Sudden Cardiac Death while on Azithromycin
- Antifungals
- Other agents
VII. Causes: Miscellaneous Agents
-
Antihistamines and other Anticholinergics
- Hydroxyzine (associated more with QT Prolongation than other Antihistamines)
- Diphenhydramine
-
Opioids
- Highest risk agents: Methadone, Buprenorphine, Oxycodone
- Consider lower risk agents: Morphine
- Sympathomimetics
- Seratonin Agonists
VIII. Causes: Medications that more commonly cause Torsades
IX. Causes: Medications that less frequently cause Torsades
- Amiodarone
- Arsenic Trioxide
- Chlorpromazine
- Cisapride
- Clarithromycin
- Domperidone
- Droperidol
- Erythromycin
- Halofantrine
- Haloperidol
- Lidoflazine
- Mesoridazine
- Pentamidine
- Pimozide
- Sparfloxacin
- Thioridazine
X. Labs
- Basic metabolic panel
- Serum Magnesium
XI. Imaging
- Consider Echocardiogram
- Excludes structural heart disease
XII. Management
- Stop offending agent
- Correct Electrolyte abnormalities, considering 5H5T causes (esp. Potassium abnormalities)
- Consider Magnesium Sulfate 1-2 grams prophylactically
- Indications to consider telemetry admission
- QTc Interval >500 ms
- QTc Interval increased 60 ms over baseline
- T-Wave alternans
- Atrioventricular Block
- QRS Widening
- Syncope
- Manage Torsades de Pointes
- See Torsades de Pointes
- Electrical cardioversion (Nonsynchronized)
- Magnesium Sulfate 2 grams
- May be repeated in 5-15 minutes
- May be continued as infusion Magnesium 3 to 20 mg/min IV for Prolonged QTc
- Overdrive pacing
- Set at rate >100 bpm
- Other measures
- Isoproterenol has been used historically and is generally not recommended
- Dosing was bolus and infusion with titrate to Heart Rate >100 bpm
- Isoproterenol has been used historically and is generally not recommended
XIII. Prevention
- Avoid combining agents at risk for QTc Prolongation
- Exercise caution in prescribing agents that prolong QTc in patients with underlying risk factors
- Use the lowest effective dose for agents at risk of QTc Prolongation
- Consider baseline EKG prior to administering QTc prolonging agent
- Avoid these agents if elevated QTc (>450 to 460 ms)
- Stop these agent if QTc increases >60 ms or QTc >500 ms
XIV. References
- (2022) Presc Lett 29(8): 44-5
- Glauser and Peters (2016) Crit Dec Emerg Med 30(4): 17-27
- Drew (2017) J Am Coll Cardiol 55(9): 934-47 +PMID:20185054 [PubMed]
- Roden (2004) N Engl J Med 350:1013-22 [PubMed]
- Wexler (2011) Am Fam Physician 84(1): 63-9 [PubMed]